Startseite Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves’ disease: efficacy and adverse reactions during initial treatment and long-term outcome
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves’ disease: efficacy and adverse reactions during initial treatment and long-term outcome

  • Hirokazu Sato EMAIL logo , Masanori Minagawa , Nozomu Sasaki , Shigetaka Sugihara , Itsuro Kazukawa , Kanshi Minamitani , Kunio Wataki , Susumu Konda , Hiroaki Inomata , Kazunori Sanayama und Yoichi Kohno
Veröffentlicht/Copyright: 1. Juni 2011
Journal of Pediatric Endocrinology and Metabolism
Aus der Zeitschrift Band 24 Heft 5-6

Abstract

Objective: The aim of this study was to compare the efficacy and adverse reactions during initial treatment and long-term outcome between children and adolescents with Graves’ disease (GD) treated with propylthiouracil (PTU) and those treated with methimazole (MMI).

Design, setting and participants: Retrospective and collaborative study. Children and adolescents with GD were divided into group M (MMI: n=64) and group P (PTU: n=69) and into four subgroups by initial dose: group M1 (<0.75 mg/kg of MMI, n=34), group M2 (≥0.75 mg/kg, n=30), group P1 (<7.5 mg/kg of PTU, n=24) and group P2 (≥7.5 mg/kg, n=45).

Main outcome measures: The duration for normalization of serum T4 on initial treatment, the incidence of adverse effects for one year and outcomes at 10 years after were compared.

Results: Mean durations for normalization of T4 (±SD) were 1.7±1.0 months in group M and 2.3±2.4 in group P [not significant (NS)], while the mean duration in group P1 (3.1±3.3) was significantly longer than those in the other subgroups (M1: 1.9±1.2; M2: 1.4±0.7; P2; 1.7±1.3). No major adverse reaction was observed. Minor adverse effects occurred in 25.0% of cases in group M and 31.9% in group P (NS). The incidence in group P2 (44.4%) was significantly higher than those in group M1 (20.6%) and group P1 (8.3%). Remission rates did not differ between the MMI-treated group (35.0%, n=20) and PTU-treated group (50.0%, n=40).

Conclusions: PTU may not be suitable for initial use in children and adolescents with GD, even with the risk of major adverse reactions such as liver failure excluded.


Corresponding author: Hirokazu Sato, Sunrise Children’s Clinic, Nakayama Medical Square 1F, 4-22-10 Motonakayama, Funabashi, Chiba 273-0035, Japan Phone: +81 47 3338222, Fax: +81 47 3332733

Published Online: 2011-06-01
Published in Print: 2011-06-01

©2011 by Walter de Gruyter Berlin Boston

Artikel in diesem Heft

  1. Publisher's Note
  2. Publisher's Note
  3. Editorial
  4. The damage caused by incomplete and uncontrolled medical information
  5. Images in Pediatric Endocrinology
  6. Dorsolumbar kyphosis: diagnostic value of hook shaped vertebra
  7. Original Contributions
  8. Are adolescent weight-related problems and general well-being essentially an issue of age, gender or rather a pubertal timing issue?
  9. Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves’ disease: efficacy and adverse reactions during initial treatment and long-term outcome
  10. The effect of glucocorticoid replacement therapy on bone mineral density in children with congenital adrenal hyperplasia
  11. Treatment of symptomatic osteoporosis in children: a comparison of two pamidronate dosage regimens
  12. Stanozolol regulates proliferation of growth plate chondrocytes via activation of ERα in GnRHa-treated adolescent rats
  13. A case of McCune-Albright syndrome associated with pituitary GH adenoma: therapeutic process and autopsy
  14. The role of metabolic syndrome components and adipokines in insulin resistance in prepubertal children
  15. A new heterozygous mutation (D196N) in the Gs alpha gene as a cause for pseudohypoparathyroidism type IA in a boy who had gallstones
  16. Causes and patterns of referral to a tertiary, multidisciplinary program for the treatment of childhood obesity
  17. Vitamin D receptor genotypes are associated with bone mass in patients with Turner syndrome
  18. Plasma leptin and adiponectin concentrations in healthy, non-obese children
  19. Puberty and pubertal growth dynamics in children with idiopathic short stature
  20. Endocrine complications following pediatric bone marrow transplantation
  21. Rare hypertension as a result of 17α-hydroxylase deficiency
  22. Girls with early puberty attain a near-final height similar to their target height
  23. Persistent hyperthyrotropinemia in congenital hypothyroidism: successful combination treatment with levothyroxine and liothyronine
  24. Benign transient hyperphosphatasemia in infants and children: a prospective cohort
  25. The relation between 25-hydroxyvitamin D with peak bone mineral density and body composition in healthy young adults
  26. Childhood obesity: evidence of an association between plasminogen activator inhibitor-1 levels and visceral adiposity
  27. Glargine basal-bolus insulin regimen versus insulin pump therapy: comparison of glycemic control
  28. Patient Report Letters
  29. A new variant of a known mutation in two siblings with permanent neonatal diabetes mellitus
  30. HNF1A mutation presenting with fetal macrosomia and hypoglycemia in childhood prior to onset of overt diabetes
  31. A newborn case with perinatal-lethal Gaucher disease due to R463H homozygosity complicated by C677T homozygosity in the MTHFR gene
  32. Hyperthyroidism presenting with hyperglycemia in an adolescent female
  33. Short Communications
  34. A single base-pair deletion in the WFS1 gene causes Wolfram syndrome
  35. Growth suppression caused by corticosteroid eye drops
  36. Familial glucocorticoid deficiency due to compound heterozygosity of two novel MC2R mutations
  37. Letter to the Editor
  38. Meetings
  39. Meetings Calendar
Heruntergeladen am 15.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jpem.2011.194/html
Button zum nach oben scrollen